Chronic Myeloid Leukemia Clinical Trials in Philadelphia, Pennsylvania

3 studies are recruiting for chronic myeloid leukemia in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Olverembatinib (HQP1351) in Patients With CML-CP

    Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure c…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ascentage Investigative Site #1057, Philadelphia, Pennsylvania
    Locations
    163 in total
    Run by
    Ascentage Pharma Group Inc.

    See if you can join NCT06423911 on ClinicalTrials.gov

  2. A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

    Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be admin…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Locations
    11 in total
    Run by
    Crossbow Therapeutics, Inc.

    See if you can join NCT06994676 on ClinicalTrials.gov

  3. A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

    The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML). The study has two parts: Part 1…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University - Center City (Philadelphia), Philadelphia, Pennsylvania
    Locations
    54 in total
    Run by
    Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    See if you can join NCT06163430 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.